|

|

Area Editoriale


30/12/2021

COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation

Clinical Gastroenterology and Hepatology 12.2021

04/11/2021

Mistakes in colonoscopic surveillance in IBD and how to avoid them

UEG Education, 2021 - Matthew D Rutter

01/10/2021

Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.

William J. Sandborn et al., NEJM September 30th, 2021

28/08/2021

Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial

Séverine Vermeire, William J Sandborn et al. Journal of Crohn's and Colitis, 17 August 2021

04/08/2021

Comparative Efficacy for Infliximab vs. Vedolizumab in Biologic Naive Ulcerative Colitis

Neeraj Narula, MD, MPH, FRCPC, Jean-Frederic Colombel, MD, Walter Reinisch, MD, PhD Published CGH July 27, 2021 DOI:https://doi.org/10.1016/j.cgh.2021.07.038

03/07/2021

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study

Journal of Crohn's and Colitis, 02 June 2021 Marc Ferrante, Brian G Feagan, et al.

05/06/2021

Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn’s Disease in Endoscopic Remission.

Clinical Gastroenterology and Hepatology June_2021 - Anne B. Hu, William Tan,Vikram Deshpande, and Ashwin N. Ananthakrishnan.

11/05/2021

STRIDE II An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Gastroenterology, 04/2021

04/04/2021

Ultrasonography tight control and monitoring in Crohn’s disease during different biological therapies: a multicenter study

E. Calabrese, A. Rispo, F. Zorzi, E. De Cristofaro, A. Testa, G. Costantino, A. Viola, C. Bezzio, C. Ricci, S. Prencipe, C. Racchini, G. Stefanelli, M. Allocca, M. Cappello, G. Maconi, A. Spagnoli, G. Monteleone, F. Castiglione et al

03/03/2021

Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: the IM-UNITI trial

Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJ, Colombel J-F, Feagan BG, Lynch JP. Clinical Gastroenterology and Hepatology (2021), doi: https://doi.org/10.1016/j.cgh.2021.02.025.

17/02/2021

Ustekinumab for Ulcerative colitis

Reena Khanna, MD, Waqqas Afif, MD. Gastroenterology (2021) https://doi.org/10.1053/j.gastro.2021.02.002.

28/01/2021

Incidence of and risk factors for colorectal strictures in ulcerative colitis: a multicenter study

Pierre-Antoine Laurain ∗ Laurent Peyrin-Biroulet. Clinical Gastroenterology and Hepatology January 21, 2021 - DOI: https://doi.org/10.1016/j.cgh.2021.01.028